Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Slides:



Advertisements
Similar presentations
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Advertisements

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Optimizing Statin Therapy
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Omega-3 Prescriptions vs Supplements in Practice
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
Obesity and Dyslipidemia: How Would You Treat?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statin Selection in Special Patient Populations: A Case Challenge
What Do We Know About LDL-C?
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
PCSK9 Inhibitors and Cardiovascular Outcomes
Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Exploring Statin Intolerance
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Lipid Clinic Challenge
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Aspirin and Cardioprevention in 2018
Clinicians' Corner in Dyslipidemia
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Statins, Obesity, and Hyperlipidemia
Glucose Management and Statin Therapy
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
DECLARE-TIMI 58.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
Glucose Management and Statin Therapy
Omega-3s vs Pure EPA in Clinical Practice
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
The Power of As-Treated Analyses
Presentation transcript:

Exploring the Latest Statin Clinical Data in CAD: How to Treat High-Risk Patients?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Residual CV Risk in Major Statin Trials

CHD Events Occur in Patients Treated With Statins

Residual CVD Risk in Patients With Diabetes Treated With Statins

Patients With Established CVD

Residual Risk in Patients Treated With High- Intensity Statins

Many Issues at Play -- Use a Team Approach

Low-Dose vs High-Dose Statins

Win-Win With a Team Approach

Helping Patients Understand the Challenges

REAL-CAD

REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/UA

Serial Changes in Lipid Parameters and hs-CRP

Importance of Targeting LDL-C

Genetics: Very Low LDL-C Only Benefit

Statin Rx in Patients With ASCVD

What Are Your Patients' Needs and Risks What Are Your Patients' Needs and Risks? Pick the Right Statin for Your Patient

Statins, ASCVD, VA Hospitals

Create a System That Supports Your Knowledge

Abbreviations

Abbreviations (cont)